News

Inventiva's Ordinary Shares Resume Trading on Euronext Paris

Inventiva's Ordinary Shares Resume Trading on Euronext Paris

Inventiva Announces Trading Resumption on Euronext Paris

Daix, France – Inventiva (Euronext Paris and Nasdaq: IVA) announced the resumption of trading for its ordinary shares on Euronext Paris, effective 4:30 p.m. CET. This decision follows a temporary halt in trading initiated by the company, aimed at facilitating its recently announced public offering.
Trading had been paused on November 13, at 9:00 a.m. CET, to finalize investor allocations and disclose pricing details for the American Depositary Shares, each corresponding to one new ordinary share of the company, with a nominal value of €0.01.

About Inventiva

Inventiva is a dedicated biopharmaceutical company focused on the creation and advancement of oral therapies for metabolic dysfunction-associated steatohepatitis (MASH). One of the company's key products, lanifibranor, is currently undergoing evaluation in the NATiV3 pivotal Phase 3 clinical trial, designed for adult patients suffering from MASH, known for being a prevalent and progressive chronic liver disease.

Investing in Innovating Treatments

Listed on Euronext Paris as IVA and also on Nasdaq, Inventiva is committed to creating solutions that significantly improve the quality of life for patients with chronic diseases. The company’s investments in research and development are rooted in a strong commitment to innovation and addressing unmet medical needs. This focus positions Inventiva as a promising player in the biopharmaceutical landscape, particularly in the context of MASH, which affects millions globally.

Recent Developments

Recent studies and advancements indicate a resolute path ahead for Inventiva. The NATiV3 trial results are eagerly anticipated, as they hold the potential to elevate the visibility of lanifibranor and further bolster the company’s portfolio. Positive outcomes from these trials could possibly lead to an expanded market presence and improved investor confidence.

Company Leadership and Strategy

Under the strategic guidance of Pascaline Clerc, EVP of Strategy and Corporate Affairs, Inventiva is navigating the complexities of pharmaceutical development with a focus on sustainable growth and innovation. The team's expertise is crucial for ensuring the successful development and market introduction of their pipeline products.

Contact Information

Inventiva
Pascaline Clerc
EVP, Strategy and Corporate Affairs
Email: media@inventivapharma.com
Phone: +1 202 499 8937

ICR Healthcare Media Relations
Alexis Feinberg
Email: inventivapr@icrhealthcare.com
Phone: +1 203 939 2225

ICR Healthcare Investor Relations
Patricia L. Bank
Email: patti.bank@icrhealthcare.com
Phone: +1 415 513 1284

Frequently Asked Questions

What is the significance of the trading resumption for Inventiva?

The resumption indicates a new phase for Inventiva as it moves forward with its public offering and seeks further investments for growth.

What therapies is Inventiva currently developing?

Inventiva is mainly focused on therapies for metabolic dysfunction-associated steatohepatitis (MASH), particularly the novel drug lanifibranor.

Where is Inventiva publicly listed?

Inventiva is listed on Euronext Paris under the ticker IVA and also on the Nasdaq Global Market.

Who is involved in Inventiva's corporate affairs?

Pascaline Clerc, as EVP of Strategy and Corporate Affairs, plays a key role in steering the company’s direction.

How can I get in touch with Inventiva for more information?

You can reach Inventiva through the provided email addresses for media and investor relations for inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 1

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
Davos Healthcare Aims to Revolutionize Hospital Ratings

Updated Category News Views 0

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 1

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Anecdotes by Artists Brings Raw Scent Stories to Sephora

Updated Category News Views 1

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 5

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 1

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 7

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading

Top 5 Most Recently Viewed Articles

Miracle Journey of Rayne Beau: A Cat's 900-Mile Return Home

Updated Category News Views 283

Reuniting with a Beloved Pet In an inspiring tale of loyalty and perseverance, a two-and-a-half-year-old Siamese cat named Rayne Beau captured attention after reuniting with his dedicated owners, Susanne and Benny Anguiano. After mysteriously wandering off during their trip, this fluffy companion undertook an extraordinary journey of over 900 miles to return home, taking...

Continue Reading
Teknova Teams Up with Pluristyx to Enhance Cell Therapy Production

Updated Category News Views 187

Teknova and Pluristyx Partnership for Cell Therapy Innovation HOLLISTER, Calif. – Teknova, known for its critical reagents in life sciences, has joined forces with Pluristyx to enhance the manufacturing of next-generation cell therapies. This collaboration aims to produce and distribute the PluriFreeze™ product line, which serves as both a cryopreservative and cell...

Continue Reading
XP Investors Potential for Class Action Against Securities Fraud

Updated Category News Views 156

XP Inc. Investors Considering Class Action Lawsuit XP Inc. (NASDAQ: XP) has found itself at the center of a significant legal inquiry, as investors are encouraged to consider the implications of recent allegations against the company. This analysis sheds light on the potential for a class action lawsuit, which could provide a vital avenue for shareholders to seek redress...

Continue Reading
Federal Reserve Explores Enhancements for Discount Window Lending

Updated Category News Views 118

Federal Reserve's Review of Discount Window Operations The Federal Reserve is actively seeking public input on its emergency lending tool, known as the "discount window." This mechanism is specifically intended to assist banks during difficult financial times. Objectives of the Feedback Solicitation On a recent Thursday, the Fed announced its plan to gather comments...

Continue Reading
Bitcoin's Future: Will It Soar to New Heights or Dip Sharply?

Updated Category News Views 120

The Roller Coaster Ride of Bitcoin in 2025 The first half of 2025 has been an exhilarating journey for Bitcoin, marked by extreme volatility and dramatic shifts in market sentiment. Following its historic peaks and valleys, Bitcoin has once again captured the attention of both retail and institutional investors alike. From All-Time Highs to Big Dips Bitcoin recently shot...

Continue Reading